Impaired Glucose Tolerance (IGT) Completed Phase 3 Trials for Rosiglitazone (DB00412)

Back to Impaired Glucose Tolerance (IGT)

Also known as: IGT - Impaired Glucose Tolerance / Intolerance to glucose / Impaired Glucose Tolerance (Prediabetes) / Glucose tolerance impaired / Impaired Glucose Tolerance / Glucose Intolerance / Decreased carbohydrate and glucose tolerance / Glucose tolerance decreased / Decreased glucose tolerance / Latent diabetes / Abnormal glucose NOS / Chemical diabetes

Indication	Status	Phase
DBCOND0042124 (Impaired Glucose Tolerance (IGT))	Completed	3

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT01574820	Role of Rosiglitazone on Pre-Diabetes Mellitus and Coronary Artery Disease	Treatment	Rosiglitazone (DB00412)
NCT00095654	The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) Trial	Prevention	Ramipril (DB00178) Rosiglitazone (DB00412)
NCT00116922	A Lifestyle and Combination Medication Therapy Diabetes Prevention Study	Prevention	Metformin (DB00331) Rosiglitazone (DB00412)
NCT00140647	The Study of Atherosclerosis With Ramipril and Rosiglitazone	Prevention	Ramipril (DB00178) Rosiglitazone (DB00412)
NCT00489229	To Investigate the Effect of Rosiglitazone and Ramipril on Pre-clinical Vasculopathy in Diabetes and IGT Patients	Treatment	Ramipril (DB00178) Rosiglitazone (DB00412)